Abstract

Original Article

Preliminary report on a sargramostim inhalation study for moderate to severe autoimmune alveolar proteinosis

Koh Nakata^a  Tomohiro Handa^b  Takuro Sakagami^c  Takuji Suzuki^d  Yoshinori Tanino^e  Keiichi Akasaka^f  Satoru Ito^g  Keisuke Tomii^h  Noriho Sakamotoⁱ  Ryosuke Eda^j  Hirokazu Kimura^k  Nobutaka Kitamura^a 

^aDivision of Pioneering Advanced Therapeutics, Niigata University Medical and Dental General Hospital
^bDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine
^cDepartment of Respiratory Medicine, Kumamoto University Hospital
^dDepartment of Respirology, Graduate School of Medicine, Chiba University
^eDepartment of Respiratory Medicine, Fukushima Medical University
^fDepartment of Respiratory Medicine, Saitama Red Cross Hospital
^gDepartment of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine
^hDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital
ⁱDepartment of Respiratory Medicine, Nagasaki University Hospital
^jDepartment of Internal Medicine (Respiratory Medicine), Kurashiki Municipal Hospital
^kDepartment of Respiratory Medicine, Hokkaido University Graduate School of Medicine

ABSTRACT

KEYWORDS

Autoimmune pulmonary alveolar proteinosis (APAP)  Sargramostim  Inhalation therapy  Alveolar-arterial oxygen difference (A-aDO₂)  Anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody